Peptide
PT-141
SaveBremelanotide, a cyclic melanocortin peptide that activates MC4R in the CNS to produce pro-sexual effects. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Quick verdict
One of the few peptides on this list with FDA approval. Demonstrated efficacy for female HSDD. Nausea is a significant side effect.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Two pivotal RCTs (RECONNECT) led to FDA approval in 2019. Statistically significant improvement in sexual desire. Nausea affected ~40% of patients. Also studied for male erectile dysfunction.
Benefits
- FDA-approved for hypoactive sexual desire disorder
- CNS mechanism distinct from peripheral vasodilators
- Demonstrated efficacy in pivotal RCTs
Dosage notes
Vyleesi: 1.75 mg subcutaneously at least 45 minutes before anticipated activity. Maximum 8 doses/month.
Side effects
- Nausea (40%+)
- Flushing
- Headache
- Transient blood pressure elevation
- Injection-site reactions
- Skin hyperpigmentation with repeated use
Who should be cautious
FDA-approved for premenopausal women only. Not for use with cardiovascular disease. Causes transient blood pressure increase. Limited to 8 doses per month per label.
What this page cannot tell you
Effect size is modest. High nausea rate limits tolerability. Male ED use is off-label and less well studied.
Leaderboard scores
- Libido55
Write a review
Sign in to write a review.